BMS-986263治疗晚期肝纤维化:36周随机安慰剂对照2期试验结果
一项在美国肝病门诊开展的2期随机安慰剂对照试验,纳入HCV持续病毒学应答且晚期肝纤维化患者61例,每周静脉输注BMS-986263(45或90 mg)或安慰剂共12周。第12周METAVIR改善≥1级比例分别为安慰剂13%、45 mg组17%、90 mg组21%;90 mg组5例Ishak改善≥2级。不良事件均为轻中度,36周内总体耐受良好。
要点
- BMS-986263 45/90 mg每周静脉输注12周,METAVIR改善率分别为17%和21%,安慰剂为13%。
- 90 mg组有5例Ishak评分改善≥2级,所有不良事件均为轻中度。
- 基线胶原水平低提示纤维化生成不活跃,需在活跃纤维化患者中进一步评估。
核心结论
- 在HCV持续病毒学应答且晚期肝纤维化患者中,BMS-986263至第36周总体耐受良好,并带来METAVIR和Ishak评分改善。
研究设计与样本
- NCT03420768为2期、随机(1:1:2)、安慰剂对照试验,在美国一家肝病门诊开展。
- 纳入HCV持续病毒学应答≥1年且晚期肝纤维化患者,每周静脉输注安慰剂或BMS-986263(45或90 mg)共12周。
- 主要终点为第12周METAVIR分期改善≥1级;关键次要终点包括Ishak评分改善、药代动力学、纤维化生物标志物和安全性。
- 共61例患者全部完成治疗。
主要发现
- 第12周METAVIR改善≥1级:安慰剂组2/15(13%)、45 mg组3/18(17%)、90 mg组6/28(21%)。
- 90 mg组有5例患者Ishak评分改善≥2级。
- BMS-986263血浆浓度在两个剂量间呈总体剂量比例增加,每周给药无明显蓄积。
- 所有不良事件均为轻或中度;大多数治疗相关不良事件为BMS-986263组的输注相关反应。
- 基线胶原水平低,提示这些患者纤维化生成水平低。
临床怎么用
- 对于HCV持续病毒学应答后晚期肝纤维化患者,BMS-986263 45或90 mg每周静脉输注12周总体耐受良好。
- 现有数据提示BMS-986263可能改善METAVIR和Ishak评分,但需在纤维化生成活跃的患者中进一步评估。
局限性
- 基线胶原水平低,提示入组患者纤维化生成不活跃,可能影响疗效评估。
- 原文未报告研究局限性相关表述。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Hepatic fibrosis secondary to HCV infection can lead to cirrhosis and hepatic decompensation. Sustained virologic response (SVR) is possible with direct-acting antiviral drug regimens; however, patients with advanced fibrosis have an increased risk for HCC. Heat shock protein 47 (HSP47), a key collagen chaperone, has been implicated in fibrosis development. We evaluated the efficacy and safety of BMS-986263, a lipid nanoparticle delivering small interfering RNA designed to degrade HSP47 mRNA, for the treatment of advanced fibrosis. APPROACH AND RESULTS: NCT03420768 was a Phase 2, randomized (1:1:2), placebo-controlled trial conducted at a hepatology clinic in the United States. Patients with HCV-SVR (for ≥ 1 year) and advanced fibrosis received once-weekly i.v. infusions of placebo or BMS-986263 (45 or 90 mg) for 12 weeks. The primary endpoint was ≥ 1 METAVIR stage improvement at Week 12; key secondary endpoints included Ishak score improvement, pharmacokinetics, fibrosis biomarkers, and safety. All 61 patients completed treatment, and 2/15 (13%, placebo), 3/18 (17%, 45 mg), and 6/28 (21%, 90 mg) had METAVIR improvements of ≥ 1 stage at Week 12. Five patients in the 90-mg arm had Ishak improvements by ≥ 2 stages. BMS-986263 plasma concentrations increased in a generally dose-proportional fashion between BMS-986263 doses, with no notable accumulation with weekly dosing. All adverse events (AEs) were mild or moderate in intensity; most treatment-related AEs were infusion-related reactions in the BMS-986263 arms. At baseline, collagen levels were low, indicating low levels of fibrogenesis in these patients. CONCLUSIONS: In patients with HCV-SVR, BMS-986263 administration was generally well tolerated through Week 36 and resulted in METAVIR and Ishak score improvements. Further evaluation of BMS-986263 in patients with active fibrogenesis is warranted.
引用
- Lawitz EJ, Shevell DE, Tirucherai GS, et al. BMS-986263 in patients with advanced hepatic fibrosis: 36-week results from a randomized, placebo-controlled phase 2 trial. Hepatology. 2021. PMID: 34605045. doi:10.1002/hep.32181
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。